AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02176642 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Tibial Nerve Stimulation
Description: In office therapy administered for 30 minutes once every week for a total of 6 weeks
Study NCT02176642 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Posterior Tibial Nerve Stimulation
Description: In office therapy administered for 30 minutes once every week for a total of 6 weeks
Study NCT02176642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet taken by mouth daily for 6 weeks
Study NCT04196270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: In a dose finding study the total volume of ropivacaine changes according to the biased coin up-and-down sequential design
Study NCT01783899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemospray
Description: Patients will be resuscitated as needed to achieve hemodynamic stability in preparation for endoscopy within 24 hours of hospital admission.~once the bleeding point will be identified at endoscopy, the delivery catheter will be inserted through the endoscope and positioned toward the lesion, leaving 1-2 cm between the bleeding site and the catheter tip.~Hemospray will be then delivered in short spray bursts (for 1-2 seconds) until hemostasis was confirmed.~Once bleeding was controlled , the bleeding site will be observed for 5 minutes under endoscopy.~Oral food and fluid will be with held from the patient for 24 hours. Intravenous octreotide and esomeprazole will given for up to 24 hours. Patients will be closely monitored for signs of recurrent bleeding for 24 hours post procedure.~Recurrent bleeding will be diagnosed any patient experiencing recurrent bleeding will treated according to the institutional standard of care
Study NCT03128073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carry life system, ultrafiltration (CLS UF)
Description: The addition of Glucose-salt intermittently to a volume of the intraperitoneal fluid in the device which is then returned to the subject.
Study NCT02574260 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Administered by intratumoral injection.
Study NCT02609178 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FGP
Description: To execute FGP technique, the occlusal surface of the interim should be back cut to leave at least 1mm occlusal space. Then apply the recording resin. Ask the subjects to close the mouth to maximum intercuspal position then perform right lateral, left lateral and protrusive movements in succession ending in maximum intercuspation position. Excessive resin then should be trimmed off and Bausch articulating paper would be used to mark the intercuspal contacts. Zinc oxide is then applied to check eccentric occlusion, trimmed off resin if there're interferences. Then the interim would be used as a copy to design the occlusal surface of the crown. (CAD/CAM)
Study NCT02609178 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AVR
Description: the crowns in this group would be designed by setting virtual articulator to average mode (CAD/CAM)
Study NCT01598415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR113945
Description: Pharmaceutical form:Injection~Route of administration: Intra-articular
Study NCT01598415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:Injection~Route of administration: Intra-articular
Study NCT03749525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: shenfu injection
Description: we hypothesis that shenfu injection could improve patients' arterial vascular reactivity with septic shock
Study NCT03749525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: shenfu injection
Description: we hypothesis that shenfu injection could improve patients' arterial vascular reactivity with septic shock
Study NCT03644459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYN00101
Description: Concentrate for intravenous infusions (10 mg / ml) with Molecular Weight 150 - 151 kDa.~Each cycle of treatment consists of 24 weeks. Patients who enroll into this study will receive an infusion of assigned dose of LYN00101 biweekly. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 10mg/kg, starting from 8 mg/kg.
Study NCT01185639 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: For lung, liver, axial skeleton, and adrenal tumors a dose of either 54 Gy in 3 fxs or 5000 cGy in 5 fx using SBRT techniques
Study NCT01364259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: Amifostine and CyberKnife stereotactic radiosurgery
Study NCT00376259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adefovir dipivoxil
Description: 10 mg of adefovir by mouth once daily
Study NCT00376259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adefovir dipivoxil
Description: 10 mg of adefovir by mouth once daily
Study NCT01364259 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: CyberKnife stereotactic radiosurgery
Description: CyberKnife stereotactic radiosurgery
Study NCT02540720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT01699672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group information
Description: The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
Study NCT03653962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video assisted group
Study NCT03653962 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: non-video group
Study NCT03653962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: non-video group
Study NCT03517176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEND-1
Description: CEND-1 will be provided as concentrate for solution to be administered via IV injection.
Study NCT03517176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be provided as solution to be administered via IV infusion.
Study NCT03517176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be provided as solution to be administered via IV infusion.
Study NCT02858804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 50 mg/m2, IV d1-4
Study NCT02858804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 10 mg/m2, IV, d1-4
Study NCT02540720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma globulin
Study NCT02540720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemoperfusion
Study NCT02858804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 30 mg/d, d1-5
Study NCT03957317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye mask and ear plugs
Description: Subjects receive one pair of eye mask and ear plugs during their stay in the surgical ICU.
Study NCT02858804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 0.4 mg/m2, IV, d1-4
Study NCT02858804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 ,d5
Study NCT02858804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2g/m2, q12h, d1
Study NCT02858804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100mg/ m2,IV, d1
Study NCT02858804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV, d1
Study NCT02858804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 50-150mg/d, po, d1-28
Study NCT02858804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 0.5mg/Kg, po, qod
Study NCT05682209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide Injection
Description: 100µg of octreotide intravenously 8-hourly for 5 days from the first post-operative day
Study NCT05682209 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: 1ml of sterile water intravenously 8-hourly for 5 days from the first post-operative day
Study NCT00386100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avandamet 6 mg/1500 mg (ttd)
Description: One 2 mg/ 500 mg capsule will be taken in the AM with the morning meal Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal
Study NCT01616836 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous FNB
Description: femoral nerve block (ropivacaine 0.5%, 20 mL) with femoral nerve block infusion 48 h (ropivacaine 0.2%, 5mL/h), placebo local infiltration
Study NCT01616836 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: single femoral nerve block
Description: single femoral nerve block (ropivacaine 0.5%, 20 mL), placebo femoral nerve block infusion, placebo local infiltration
Study NCT01616836 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: local infiltration analgesia
Description: placebo fascia iliac block, placebo fascia iliaca infusion, local infiltration analgesia (tricompartmental injection of 150 mL ropivacaine 0.2%, ketorolac 30 mg, epinephrine 10 microg/mL)
Study NCT00386100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avandamet 4 mg/1000 mg (ttd)
Description: One 2 mg/500 mg capsule will be taken in the AM with the morning meal. One 2 mg/500 mg capsule will be taken in the PM with the evening meal.
Study NCT00386100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avandamet 2 mg/500 mg (ttd)
Description: one placebo capsule will be taken in the AM with the morning meal one 2 mg/ 500 mg capsule will be taken in the PM with the evening meal.
Study NCT00386100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avandamet 8 mg/ 2000 mg (ttd)
Description: Two 2 mg/ 500 mg capsules will be taken in the AM with the morning meal. Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal.
Study NCT00386100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin 500 mg (ttd)
Description: One placebo capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
Study NCT00386100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin 1000 mg (ttd)
Description: One 500 mg capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
Study NCT00386100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin 1500 mg (ttd)
Description: One 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsules will be taken in the PM with the evening meal.
Study NCT00386100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin 2000 mg (ttd)
Description: Two 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsule will be taken in the PM with the evening meal.
Study NCT03015909 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Somatropin
Study NCT00656396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coagucheck XS Plus (Point of care monitor of coagulation intraoperative)
Description: Coagucheck XS Plus® is used for intraoperative measurement of Prothrombin time
Study NCT00656396 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: Standard care
Study NCT00731510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate energy drink
Description: Complex carbohydrates including maltodextrin (97%) dissolved in water to make a a 10% solution, or dissolved in 25mL gels. Ad libitum. Twenty two days.
Study NCT00731510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Aspartame
Description: Aspartame dissolved in water, ad libitum, 22 days.
Study NCT01166997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EkoSonic Endovascular System
Description: The EkoSonic Endovascular System will be used to deliver \< 20 mg of rt-PA ( Actilyse) directly into the occlusive pulmonary thrombus.
Study NCT01166997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Intravenous unfractionated heparin used for anticoagulation treatment
Study NCT01997099 — intervention group
Intervention type: DEVICE
Intervention: CADD®-Solis VIP Pump
Study NCT01997099 — intervention group
Intervention type: DEVICE
Intervention: CADD™ Solis Medication Safety Software Administrator
Study NCT00858234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat (MK-0683) three or four 100 mg capsules taken by mouth with food.
Study NCT00858234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib (1.0 or 1.3 mg/m\^2) intravenous infusion.
Study NCT03156582 — intervention group
Intervention type: OTHER
Intervention: Data collecting
Study NCT03333382 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic biliary stent
Description: Plastic biliary stent which functions largely as a wick to siphon bile flow from the site of anastomotic leak.
Study NCT03333382 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FCSEMS
Description: FCSEMS has a relatively larger expansile diameter and membrane coating to provide an actual seal at site of anastomotic leak.
Study NCT03354923 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PEERS intervention
Description: PEERS is a 14-week manualized social skills treatment program that targets the friendship skills of adolescents with ASD. In the Israeli adaptation of PEERS, two meeting were extended. An adolescents group will be held concurrently with the parents group in different rooms. Both groups will begin the session with homework review, followed by a didactic social skills lesson, utilizing the teaching methods of modeling and role-playing. In order to practice the newly learned social skills,a behavioral rehearsal interaction will be assigned in the adolescents group. Finally,Socialization homework assignments designed to address further mastery and generalization of newly learned skills within the natural social environment will be assigned too.
Study NCT03354923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS intervention
Description: PEERS is a 14-week manualized social skills treatment program that targets the friendship skills of adolescents with ASD. In the Israeli adaptation of PEERS, two meeting were extended. An adolescents group will be held concurrently with the parents group in different rooms. Both groups will begin the session with homework review, followed by a didactic social skills lesson, utilizing the teaching methods of modeling and role-playing. In order to practice the newly learned social skills,a behavioral rehearsal interaction will be assigned in the adolescents group. Finally,Socialization homework assignments designed to address further mastery and generalization of newly learned skills within the natural social environment will be assigned too.
Study NCT03901222 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: 20 minutes of anodal tDCS (C3 \& C4/FPZ) 2mA or sham
Study NCT03901222 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: 20 minutes of anodal tDCS (C3 \& C4/FPZ) 2mA or sham
Study NCT03409497 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Concord Grape Juice
Description: Concord Grape Juice
Study NCT03409497 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low flavonoid low essence beverage
Description: Low flavonoid low essence beverage
Study NCT03409497 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low flavonoid beverage
Description: Low flavonoid beverage
Study NCT00675701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsules
Study NCT00675701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lixivaptan
Description: capsules
Study NCT00675701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: tablets
Study NCT01219088 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Bupivacaine, morphine
Description: 1.8-2.5 mL of 0.5% heavy bupivacaine for spinal anesthesia 20 mL of 0.25% bupivacaine for femoral nerve block 0.1 mg of intrathecal morphine 20 mL of 0.25% bupivacaine for periarticular infiltration
Study NCT01219088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine, morphine
Description: 1.8-2.5 mL of 0.5% heavy bupivacaine for spinal anesthesia 20 mL of 0.25% bupivacaine for femoral nerve block 0.1 mg of intrathecal morphine 20 mL of 0.25% bupivacaine for periarticular infiltration
Study NCT02648399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery：BCND（bilateral central lymph node dissection）
Study NCT02648399 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: surgery：UCND（unilateral central lymph node dissection）
Study NCT03367273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: Lesional skin biopsy was taken from every patient. Also a skin biopsy was taken from every control subject
Study NCT00118573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EVAR (Endovascular repair of Abdominal Aortic aneurysm)
Description: AAA repair with endografting
Study NCT00118573 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surveillance
Description: Surveillance of AAA without any repair until AAA will reach 5.5cm, become tender or rapidly grow
Study NCT01155635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Use of Carvedilol with any dose
Study NCT01155635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Carvedilol
Description: No use of Carvedilol
Study NCT03734588 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SPK-8016
Description: adeno-associated viral vector
Study NCT02980562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycols
Description: (Split dose 2L PEG-Asc)
Study NCT02980562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl
Description: (1L PEG-Asc plus bisacodyl)
Study NCT04006691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UGN-101 instillations
Description: Treatment with UGN-101 once weekly for a total of 3-6 times; in a retrograde fashion.
Study NCT06111560 — intervention group
Intervention type: OTHER
Intervention: We do not have any interventions. This study is based on obseravation.
Description: observational retrospective study without any interventions
Study NCT00884663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: Candesartan cilexitil tablets, 16 mg once daily
Study NCT00884663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol
Description: Propranolol hydrochloride capsules 160 mg once daily, slow release formulation
Study NCT00884663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets and capsules
Study NCT02582801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-Alfatide Ⅱ PET/CT
Description: Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min
Study NCT02582801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Alfatide Ⅱ PET/CT
Description: Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min
Study NCT02215239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workplace intervention
Description: WHO Healthy Workplace Framework and Model. The intervention plan is to implement a cyclic or iterative process recommended by WHO. The process includes eight steps: (1) Mobilize; (2) Assemble; (3) Assess; (4) Prioritize; (5) Plan; (6) Do; (7) Evaluate; (8) Improve. We focus on different phases of exercise and prescribe individualized physical activity program.
Study NCT01030276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Description: Bright light therapy
Study NCT01608919 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: blood tests
Description: thromboelastogram platelet mapping
Study NCT01084408 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SeQuent®Please (Paclitaxel coated balloon)
Description: PCI of de-novo lesions
Study NCT01084408 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus™Liberté™ (Paclitaxel eluting stent)
Description: PCI of de-novo lesions
Study NCT02792296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Project: EVO Monitor
Description: Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
Study NCT01030276 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inactive placebo-light
Description: In this arm, patients will not get any bright-light therapy in a double-blind setting